
Cite this as: Mingming XU, Zhaoliang LIU, Wenhua HU, Ying HAN, Zhen WU, Sufeng CHEN, Peng XIA, Jing DU, Xumin ZHANG, Piliang HAO, Jun XIA, Shuang YANG. Mass spectrometry analysis of intact protein *N*-glycosylation signatures of cells and sera in pancreatic adenocarcinomas[J]. Journal of Zhejiang University Science B, 2024, 25(1): 51-64.
https://doi.org/10.1631/jzus.B2200652

Mass spectrometry analysis of intact protein *N*-glycosylation signatures of cells and sera in pancreatic adenocarcinomas

Key words: Pancreatic cancer, Glycosylation, Biomarker, Glycoproteomics, Mass spectrometry

Research Summary

A comprehensive approach involving MS analysis was conducted to elucidate detailed N-glycosylation changes in PDAC cell lines and sera:




Innovation points

- **PDAC-unique N-glycoforms**
  can reflect the disease pathogenesis.

- **Surgery and chemotherapy**
  can inhibit N-glycosylation in PDAC patients' sera.

- **Certain criteria was provided for the identification of ideal PDAC serum N-glycosylation biomarkers.**



Uniqueness in PDAC compared to healthy controls

The PDAC-D group is unaffected

Changes are partially or completely reversed by clinical treatment

IZUS-B